Ipamorelin selectivity claims and where they came from posts 31–57

Coming back to post #41, because the follow-up matters more than the original answer.

Effects reported at the level of appetite are the most consistently described and the most mechanistically direct for the ghrelin-receptor compounds, which is not what most people are taking them for.

Post #45 is right about the mechanism and I think understates the practical bit.

Two things can be true about ipamorelin selectivity claims at once: the mechanism is plausible and the evidence for the size of the effect is thin. Most of the argument here is people defending the first against attacks on the second.

The confident answers on ipamorelin selectivity claims and the well-sourced answers are not the same answers, which is the most useful thing I have learned reading this category.

Reconstitution volumes in this family are often small enough that dead volume in the syringe is a meaningful fraction of the dose. A fixed-needle insulin syringe is worth the trouble here specifically.

I would put a moderate confidence on that and no more.

That reframing is the whole thing. The facts I already had.

Injection-site reactions are reported more often in this family than for the incretins. Whether that is the compounds or the preparations they are typically supplied in is not established.

The strength of my opinion here exceeds the strength of my evidence.

Post #48 is right about the mechanism and I think understates the practical bit.

The honest answer on ipamorelin selectivity claims is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they matter.

Most people get the first two right and then argue about the fourth.

I read the earlier replies on ipamorelin selectivity claims twice before writing this, because I had assumed the opposite and wanted to be sure I was disagreeing with what was said rather than what I expected.

On analysis: these are short peptides and generally straightforward chromatographically, which means a poor purity result is more likely to reflect the synthesis than the method.

Why this subcategory is stricter about sourcing than most: the evidence base is weaker and that is precisely why documentation quality matters more. A supplier page that clearly identifies the compound and the purity is more valuable for secretagogues than for incretin agonists where the evidence base is stronger.

That is my reading. Someone else read the same page differently and was reasonable.

Confirming post #52 from a second method, which matters more than confirming it from a second person.

Ipamorelin is usually described as selective in that it produces less of an effect on cortisol and prolactin than earlier compounds in the family. Selective is a relative claim and the comparison group matters.

I have seen it go both ways, which is why I hedge.

I had written a reply contradicting post #54 and deleted it. Here is what survived.

My position on ipamorelin selectivity claims is current rather than settled. I have revised it once already and I expect to again, so treat it accordingly.

Ipamorelin selectivity claims came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.